BioCentury
ARTICLE | Company News

Astellas, AstraZeneca deal

January 2, 2012 8:00 AM UTC

Astellas' Prosidion Ltd. subsidiary granted AstraZeneca an exclusive option to acquire Type II diabetes compounds PSN821 and PSN842, both of which are G protein-coupled receptor 119 (GPR119) agonist...